Notice2026-00953
Notice Pursuant to the National Cooperative Research and Production Act of 1993-Biopharmaceutical Manufacturing Preparedness Consortium
Primary source
Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.
Published
January 20, 2026
Issuing agencies
Justice DepartmentAntitrust Division
Full Text
<html>
<head>
<title>Federal Register, Volume 91 Issue 12 (Tuesday, January 20, 2026)</title>
</head>
<body><pre>
[Federal Register Volume 91, Number 12 (Tuesday, January 20, 2026)]
[Notices]
[Page 2369]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2026-00953]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Antitrust Division
Notice Pursuant to the National Cooperative Research and
Production Act of 1993--Biopharmaceutical Manufacturing Preparedness
Consortium
Notice is hereby given that, on July, 24, 2025, pursuant to section
6(a) of the National Cooperative Research and Production Act of 1993,
15 U.S.C. 4301 et seq. (``the Act''), Biopharmaceutical Manufacturing
Preparedness Consortium (``BIOMAP-CONSORTIUM'') has filed written
notifications simultaneously with the Attorney General and the Federal
Trade Commission disclosing changes in its membership. The
notifications were filed for the purpose of extending the Act's
provisions limiting the recovery of antitrust plaintiffs to actual
damages under specified circumstances. Specifically, Public Health
Vaccines LLC, Cambridge, MA; International AIDS Vaccine Initiative, New
York, NY; Matisse Pharmaceuticals, B.V., Geleen, KINGDOM OF THE
NETHERLANDS; Ayala Engineering & Consulting LLC, San Antonio, TX;
Kansas State University, Manhattan, KS; Research & Development Plus
LLC, Charleston, SC; Sequence, Inc., Morrisville, NC; Xcellon
Biologics, Rockville, MD; Equitech-bio, Inc., Kerrville, TX; Lacamas
Laboratories, Inc., Portland, OR; Pluri Biotech LTD, Haifa, STATE OF
ISRAEL; Rosewater Consulting LLC, Charleston, SC; toXcel LLC,
Gainesville, VA; Biodextris, Inc., Laval, CANADA; ARNAV Biotech,
Atlanta, GA; CBRE, Inc., Radnor, PA; CMIC CMO USA Corporation,
Cranbury, NJ; F. P. Developments, Inc., Williamstown, NJ; Global
Resonance Technologies LLC, Shelburne, VT; Artis BioSolutions,
Carlsbad, CA; DSBio Consulting LLC, Annapolis, MD; OnePointOne, Inc.,
Avondale, AZ; and ViQi, Inc., Santa Barbara, CA; have been added as
parties to this venture.
No other changes have been made in either the membership or planned
activity of the group research project. Membership in this group
research project remains open, and the BIOMAP-CONSORTIUM intends to
file additional written notifications disclosing all changes in
membership.
On January 5, 2024, the BIOMAP-CONSORTIUM filed its original
notification pursuant to section 6(a) of the Act. The Department of
Justice published a notice in the Federal Register pursuant to section
6(b) of the Act on April 16, 2024 (89 FR 26923).
The last notification was filed with the Department on April 10,
2025. A notice was published in the Federal Register pursuant to
section 6(b) of the Act on January 2, 2026 (91 FR 164).
Suzanne Morris,
Deputy Director Civil Enforcement Operations, Antitrust Division.
[FR Doc. 2026-00953 Filed 1-16-26; 8:45 am]
BILLING CODE P
</pre></body>
</html>Indexed from Federal Register on January 20, 2026.
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.